CNS has a diverse and expanding pipeline of oncological solutions for GBM

Novel Additions to a Proven and Trusted Class of Medicines

There have been no major additions to the treatment options for newly diagnosed GBM patients since 2005.

Our lead product candidate, Berubicin, is an innovative, first-in-class anthraycline that appears to cross the blood brain barrier and kill tumor cells. Phase 1 clinical trial data demonstrates 44% of patients achieved a clinical response with Berubicin treatment.

Berubicin (Recurrent GBM)

Sponsor: CNS
Indication: GBM (Global, adults)
Research 100% Complete
Preclincal 100% Complete
Phase 1 100% Complete
Phase 2 50% Complete Potentially Pivotal

Berubicin (Metastases)

Sponsor: CNS
Indication: CNS Lymphoma and Metastatic Breast
Research 100% Complete 2021-2023
Preclincal 0% Complete
Phase 1 0% Complete
Phase 2 0% Complete

WP1244/WP1874

Sponsor: CNS
Indication: CNS Tumors
Research 100% Complete 2021-2023
Preclincal 0% Complete
Phase 1 0% Complete
Phase 2 0% Complete